



THE WOUND HEALING PLATFORM GENERATES A FIRST COMMERCIAL PARTNERSHIP FOR ADVITECH.

FOR IMMEDIATE RELEASE

TSX VENTURE EXCHANGE: AVI

QUEBEC CITY, QUEBEC — December 6, 2007 — Following the October 10, 2007 announcement made by Advitech (“Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) on positive pre-clinical results for wound healing applications, the Corporation announces today the signature of a letter of intent with Dectro International for the sale and marketing of a complete microdermabrasion product line. A definitive agreement must be finalized by December 31, 2007.

The IM product line, which will comprise specific dairy bioactives, generated from the XP-828L technological platform, will be a unique approach combining systemic and topical products aiming for an accelerated recovery process following a microdermabrasion procedure. The product line is a result of the Corporation’s ongoing work on both a new platform in development, and its main technological platform, XP-828L. The line will include three products: IMO-137 (oral) will be used throughout a preparation phase and after treatment, IMS-137 (topical serum) will be used immediately after the procedure and IMC-137 (cream) will be used at home by the customer to assist in the healing process.

“We are proud of this upcoming partnership with Dectro since that will allow us to commercialize a line of unique products in 2008. We have made exceptional progress, in the past few months, with this new application and expect to rapidly generate additional revenue. Dectro is a world leader in microdermabrasion and together we hope to build a strong portfolio of products around Dectro’s Gala brand name” commented Renaud Beauchesne, Advitech’s President and Chief Executive Officer. “The association Advitech-Dectro will enable us to offer a unique concept of products and solidify our leadership position”, added Mr. Clément Beaumont, President and General Manager of Dectro International.

The IM product line will be included in the Gala cosmetics line developed and sold exclusively by Dectro in estheticians clinics.

About Dectro International: www.dectro.com

For more than 20 years, Dectro International has developed and commercialized specialized devices and cosmetic products for the esthetical care market. Dectro is a world leader in microdermabrasion performed in esthetic clinics. It manages a network of exclusive distributors in all major countries. In North America, Dectro operates three distribution centers (in Quebec and California) serving more than 7,000 clinics.

About microdermabrasion:

Microdermabrasion is a cosmetic or medical procedure in which the surface of the epidermis of the skin is removed by abrasion. It is used to remove sun-damaged skin and to reduce certain scars and wrinkles.

About Advitech Inc. www.advitech.com

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech is also active in the development of wound healing applications. Recently, Advitech launched Dermylex™ for the treatment of mild-to-moderate psoriasis. The Corporation has drawn up a research program to develop new applications related to Wound Healing. This development is derived from both its XP-828L technological platform and a new colostrums platform .

-30-

This press release contains forward-looking statements which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:**Advitech Inc.**

Renaud Beauchesne, MBA
President and Chief Executive Officer
418-686-7498, ext. 228
info@advitech.com
www.advitech.com

Serge Comeau
Investor's relations
514-862-4160
s.comeau@advitech.com